Format

Send to

Choose Destination
Leuk Res. 2011 Jun;35(6):787-92. doi: 10.1016/j.leukres.2010.11.016. Epub 2011 Jan 14.

Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.

Author information

1
Drug Discovery Research, Astellas Pharma Inc., Tsukuba-shi, Ibaraki, Japan. aya.kita@jp.astellas.com

Abstract

YM155, a novel small-molecule that down-regulates survivin, exhibits broad, potent antitumor activity against a range of human tumors. We evaluated the activity of YM155 in aggressive non-Hodgkin lymphoma. In a number of diffuse large B-cell lymphoma lines, YM155 exhibited 50% growth inhibition with values between 0.23 and 3.9 nM. Within in vivo xenograft models, continuous infusion of YM155 eradicated large, established subcutaneous WSU-DLCL-2 and Ramos tumors, with sustained efficacy observed through 4 cycles of YM155 therapy. YM155 increased survival significantly versus rituximab in disseminated Ramos models. This study suggests that YM155 may represent an effective treatment for aggressive lymphomas.

PMID:
21237508
DOI:
10.1016/j.leukres.2010.11.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center